We showed previously that mouse mastocytoma P815 expresses several distinct antigens that are recognized by cytolytic T lymphocytes (CTL) of syngeneic DBA/2 mice. Antigens P815A and P815B are usually lost jointly and are targets for immune rejection responses in vivo. We used a cosmid library and a CTL stimulation assay to obtain transfectants expressing tumor rejection antigen P815A. From these transfectants we retrieved gene P1A which transferred the expression of both P815A and B. This gene is unrelated to three previously isolated genes coding for tum- antigens. It encodes a putative protein of 224 amino acids which contains two highly acidic domains showing homology with similar regions of nuclear proteins. The P1A gene expressed...
Tumor antigen P815AB is recognized by cytolytic T lymphocytes (CTL) on mouse mastocytoma P815. This ...
The cytolytic T lymphocyte (CTL) response of syngeneic mice to antigenic variants obtained by mutage...
A DNA immunization approach was used to induce an immune response against the tumor-specific antigen...
Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic c...
Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic c...
Murine mastocytoma P815 induces CTL responses against at least four distinct Ags (AB, C, D, and E), ...
In murine mastocytoma P815, gene P1A directs the expression of antigens P815A and B which are the ta...
A number of human tumor antigens have been characterized recently using cytolytic T lymphocytes (CTL...
On the basis of the results reviewed here, there are two major mechanisms whereby tumour rejection a...
Transplantation experiments have demonstrated that most mouse tumors express antigens that can const...
Experiments with mouse systems have shown that antigens recognized on tumors by cytolytic T lymphocy...
Breaking the state of immunological unresponsiveness of tumor-bearing individuals to cancer is a pre...
Most chemically induced tumors of mice express unique antigens that can be recognized by cytotoxic T...
Mutagen treatment of P815 tumour cells produces tum- variants that are rejected by syngeneic mice be...
P815 is a murine mastocytoma of DBA/2 origin which, although immunogenic, rapidly develops as a tumo...
Tumor antigen P815AB is recognized by cytolytic T lymphocytes (CTL) on mouse mastocytoma P815. This ...
The cytolytic T lymphocyte (CTL) response of syngeneic mice to antigenic variants obtained by mutage...
A DNA immunization approach was used to induce an immune response against the tumor-specific antigen...
Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic c...
Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic c...
Murine mastocytoma P815 induces CTL responses against at least four distinct Ags (AB, C, D, and E), ...
In murine mastocytoma P815, gene P1A directs the expression of antigens P815A and B which are the ta...
A number of human tumor antigens have been characterized recently using cytolytic T lymphocytes (CTL...
On the basis of the results reviewed here, there are two major mechanisms whereby tumour rejection a...
Transplantation experiments have demonstrated that most mouse tumors express antigens that can const...
Experiments with mouse systems have shown that antigens recognized on tumors by cytolytic T lymphocy...
Breaking the state of immunological unresponsiveness of tumor-bearing individuals to cancer is a pre...
Most chemically induced tumors of mice express unique antigens that can be recognized by cytotoxic T...
Mutagen treatment of P815 tumour cells produces tum- variants that are rejected by syngeneic mice be...
P815 is a murine mastocytoma of DBA/2 origin which, although immunogenic, rapidly develops as a tumo...
Tumor antigen P815AB is recognized by cytolytic T lymphocytes (CTL) on mouse mastocytoma P815. This ...
The cytolytic T lymphocyte (CTL) response of syngeneic mice to antigenic variants obtained by mutage...
A DNA immunization approach was used to induce an immune response against the tumor-specific antigen...